5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

Massimo BrecciaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, ItalyCorrespondence[email protected]

Giuseppina LoglisciDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

Adriano SalaroliDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

Alessandra SerraoDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

Luigi PetrucciDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

Marco ManciniDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

Giuliana AlimenaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

show all

References

Silverman LR, Demakos EP, Peterson BL, . Randomized, controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:2429–2440.
PubMed Web of Science ®Google Scholar
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, ; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open label, phase III study. Lancet Oncol 2009;10:223–232.
PubMed Web of Science ®Google Scholar
Itzkynson R, Thepot S, Quesnel B, ; Groupe Francophone des Myelodysplasies (GFM). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403–411.
PubMed Web of Science ®Google Scholar
Vardiman JW, Thiele J, Arber DA, . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114: 937–951.
PubMed Web of Science ®Google Scholar
Cheson BD, Greenberg PL, Bennett JM, . Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–425.
PubMed Web of Science ®Google Scholar
Campelo MD, Delgado RG, Godoy Molias AC, . Azacitidine for the treatment of myelodysplastic syndromes in the elderly. Adv Ther 2011;28:10–15.
Google Scholar
Seymour JF, Fenaux P, Silverman LR, . Effects of azacitidine compared with conventional care regimens in elderly (>75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010;76:218–227.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date